Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling.

Kauke MJ, Tisdale AW, Kelly RL, Braun CJ, Hemann MT, Wittrup KD.

Mol Cancer Ther. 2018 Aug;17(8):1773-1780. doi: 10.1158/1535-7163.MCT-17-0645. Epub 2018 May 2.

2.

Artificial Anti-Tumor Opsonizing Proteins with Fibronectin Scaffolds Engineered for Specificity to Each of the Murine FcγR Types.

Chen TF, Li KK, Zhu EF, Opel CF, Kauke MJ, Kim H, Atolia E, Wittrup KD.

J Mol Biol. 2018 Jun 8;430(12):1786-1798. doi: 10.1016/j.jmb.2018.04.021. Epub 2018 Apr 25.

3.

An engineered protein antagonist of K-Ras/B-Raf interaction.

Kauke MJ, Traxlmayr MW, Parker JA, Kiefer JD, Knihtila R, McGee J, Verdine G, Mattos C, Wittrup KD.

Sci Rep. 2017 Jul 19;7(1):5831. doi: 10.1038/s41598-017-05889-7.

4.

Cytosolic delivery of siRNA by ultra-high affinity dsRNA binding proteins.

Yang NJ, Kauke MJ, Sun F, Yang LF, Maass KF, Traxlmayr MW, Yu Y, Xu Y, Langer RS, Anderson DG, Wittrup KD.

Nucleic Acids Res. 2017 Jul 27;45(13):7602-7614. doi: 10.1093/nar/gkx546.

5.

Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses.

Kwan BH, Zhu EF, Tzeng A, Sugito HR, Eltahir AA, Ma B, Delaney MK, Murphy PA, Kauke MJ, Angelini A, Momin N, Mehta NK, Maragh AM, Hynes RO, Dranoff G, Cochran JR, Wittrup KD.

J Exp Med. 2017 Jun 5;214(6):1679-1690. doi: 10.1084/jem.20160831. Epub 2017 May 4.

6.

Temporally Programmed CD8α+ DC Activation Enhances Combination Cancer Immunotherapy.

Tzeng A, Kauke MJ, Zhu EF, Moynihan KD, Opel CF, Yang NJ, Mehta N, Kelly RL, Szeto GL, Overwijk WW, Irvine DJ, Wittrup KD.

Cell Rep. 2016 Dec 6;17(10):2503-2511. doi: 10.1016/j.celrep.2016.11.020.

7.

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.

Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, Engreitz JM, Williams RT, Rakhra K, Zhang MH, Rothschilds AM, Kumari S, Kelly RL, Kwan BH, Abraham W, Hu K, Mehta NK, Kauke MJ, Suh H, Cochran JR, Lauffenburger DA, Wittrup KD, Irvine DJ.

Nat Med. 2016 Dec;22(12):1402-1410. doi: 10.1038/nm.4200. Epub 2016 Oct 24.

8.

Durable antitumor responses to CD47 blockade require adaptive immune stimulation.

Sockolosky JT, Dougan M, Ingram JR, Ho CC, Kauke MJ, Almo SC, Ploegh HL, Garcia KC.

Proc Natl Acad Sci U S A. 2016 May 10;113(19):E2646-54. doi: 10.1073/pnas.1604268113. Epub 2016 Apr 18.

9.

Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.

Zhu EF, Gai SA, Opel CF, Kwan BH, Surana R, Mihm MC, Kauke MJ, Moynihan KD, Angelini A, Williams RT, Stephan MT, Kim JS, Yaffe MB, Irvine DJ, Weiner LM, Dranoff G, Wittrup KD.

Cancer Cell. 2015 Apr 13;27(4):489-501. doi: 10.1016/j.ccell.2015.03.004.

Supplemental Content

Loading ...
Support Center